摘要
目的评估恩替卡韦（ETV）单药对慢性乙型肝炎（CHB）初治患者的疗效。方法选择成人CHB患者150例，所有患者的血清HBV DNA≥10^5拷贝／mL，血清ALT水平为1～10ULN，且均为核苷（酸）类似物初治患者。150例患者分为两组，其中A组100例，B组50例（经检测确认无任何基因耐药者），两组患者均接受ETV单药治疗。结果经过1-2年的ETV单药治疗，A组有8例患者原发性治疗失败，6例不完全应答，5例继发性治疗失败，17例检测到耐药基因。B组患者未出现上述情况。两组相比，差异有统计学意义（P〈0．05）。结论ETV单药治疗对无基因耐药的CHB核苷（酸）类似物初治患者的疗效较好。
Objective To evaluate the effect of entecavir （ETV） monotherapy for nucleoside-naive chronic hepatitis B （CHB） patients. Methods 100 CHB adult patients were enrolled and assigned into group A, and 50 patients without pre-existing resistant genes were enrolled as group B. Patients in both groups were nucleoside-naive and with compensated liver cirrhosis, HBV DNA≥ 105 copies/mL, and ALT 1 - 10 ULN. Both groups received ETV monotherapy. Results In group A, there were 8 patients failed with the primary treatment, 6 patients had incomplete responses, 5 patients failed with the secondary treatment and the resistant genes were detected in 17 patients after 1 or 2 years treatments. The above events did not occur in group B. There was statistical difference between the two groups （ P 〈 0.05 ）. Conclusions ETV monotherapy is effective for nucleoside-naive CHB patients without pre-existing resistant genes.
出处
《国际流行病学传染病学杂志》
CAS
2009年第4期236-237,共2页
International Journal of Epidemiology and Infectious Disease
